Browsing by Author Yellon D.M.

Showing results 1 to 5 of 5
Issue DateTitleAuthor(s)
2013Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent mannerHausenloy D.J. ; Whittington H.J.; Wynne A.M.; Begum S.S.; Theodorou L.; Riksen N.; Mocanu M.M.; Yellon D.M.
2016From basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: meeting report from the third international symposium on “New frontiers in cardiovascular research”Cabrera-Fuentes H.A. ; Aragones J.; Bernhagen J.; Boening A.; Boisvert W.A.; Bøtker H.E.; Bulluck H.; Cook S. ; Di Lisa F.; Engel F.B.; Engelmann B.; Ferrazzi F.; Ferdinandy P.; Fong A.; Fleming I.; Gnaiger E.; Hernández-Reséndiz S.; Kalkhoran S.B.; Kim M.H.; Lecour S.; Liehn E.A.; Marber M.S.; Mayr M.; Miura T.; Ong S.-B.; Peter K.; Sedding D.; Singh M.K. ; Suleiman M.S.; Schnittler H.J.; Schulz R.; Shim W.; Tello D.; Vogel C.-W.; Walker M.; Li Q.O.Y.; Yellon D.M.; Hausenloy D.J.; Preissner K.T.
2013Loss of PINK1 Increases the Heart's Vulnerability to Ischemia-Reperfusion InjurySiddall H.K.; Yellon D.M.; Ong S.-B.; Mukherjee U.A.; Burke N.; Hall A.R.; Angelova P.R.; Ludtmann M.H.R.; Deas E.; Davidson S.M.; Mocanu M.M.; Hausenloy D.J. 
2018Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotectionBøtker H.E.; Hausenloy D. ; Andreadou I.; Antonucci S.; Boengler K.; Davidson S.M.; Deshwal S.; Devaux Y.; Di Lisa F.; Di Sante M.; Efentakis P.; Femminò S.; García-Dorado D.; Giricz Z.; Ibanez B.; Iliodromitis E.; Kaludercic N.; Kleinbongard P.; Neuhäuser M.; Ovize M.; Pagliaro P.; Rahbek-Schmidt M.; Ruiz-Meana M.; Schlüter K.-D.; Schulz R.; Skyschally A.; Wilder C.; Yellon D.M.; Ferdinandy P.; Heusch G.
2011Rapid assessment of myocardial infarct size in rodents using multi-slice inversion recovery late gadolinium enhancement CMR at 9.4TPrice A.N.; Cheung K.K.; Lim S.Y.; Yellon D.M.; Hausenloy D.J. ; Lythgoe M.F.